Waxa jira horumar weyn oo laga gaaray korriinka dawada buro maskaxda ee carruurnimada. Burooyinka maskaxda ee carruurtu waa cudur halis ah oo aad ugu badan carruurta. Cilmi-baaris dhawaan la sameeyay ayaa lagu ogaaday in daroogada cusub ee cocktail ay daweyn karto burooyinka maskaxda carruurnimada ee caadiga ah.
Cancer Cell” magazine recently announced that in the UK, about 400 children develop brain burooyinka each year, of which the prevalence of boys is slightly higher than that of girls.
Are we able to take advantage of the results of tumor gene testing and tailor-made treatments, a strategy often referred to as personalized medicine? This treatment strategy can produce very good results for patients with brain tumors.
Neural myeloblastoma (medulloblastoma) is one of the most common burooyinka xunxun of the cerebellum. This burada maskaxda grows rapidly and most often occurs in children around the age of 5. Doorashooyinka daaweynta include surgery, radiation, and chemotherapy. Although great progress has been made in treatment methods and techniques, the success rate of treating myeloblastoma still lags far behind other children’s malignancies. In particular, myeloblastoma is a highly aggressive malignancy. Only 40% of patients with medulloblastoma survive, compared with other tumors of a less severe type-with a survival rate of more than 80%.
Researchers in the United States have discovered a new combination therapy for the treatment of highly aggressive neuroblastoma. In laboratory tests, the drug killed kansarka cells without any toxicity to normal cells, and researchers hope to conduct clinical trials of the drug. Robert Wechsler-Reya, an adjunct professor at the Sanford Burnham Prebys Medical Institute, said: “Our goal is to confirm that the drug has low toxicity properties. Because doctors and patients in this case urgently require new clinical treatment options, we will soon apply the drug from the laboratory to clinical treatment.
Marka la isku daro daawooyinka kale, xeryahooda cusub ee xakameynaya burooyinka waxaa lagu baaraa fitamiinada iyo vivo.
Tijaabooyinka caafimaadka for neuroblastoma are often very challenging because of the limited number of patients. In addition, coupled with the variability of the disease, most treatments are only effective for one subtype of patient. Understanding which patients will respond to this treatment is one of the main goals of the trial.
"Haddii aan horumarin karno daaweyn la sameeyay oo ku saleysan hiddo-wadaha burooyinka - istiraatiijiyad badanaa loo yaqaan daaweyn shaqsiyeed-tani waxay u horseedi kartaa injiil weyn bukaanka qaba burooyinka qaarkood."
Waxaa jira afar nooc oo kala duwan oo ah neuroblastoma, bukaannada qaba koox saddexaad oo burooyin ahna waxay leeyihiin saadaasha ugu xun-40% bukaanleyda ah ayaa ka badbaada muddada dheer. Taas bedelkeeda, badbaadada muddada-dheer ee neuroblastomas kale waa mid rajo wanaagsan leh, qiyaastii 80% bukaanleyda ah ayaa ku noolaan kara muddo dheer.
Inta badan kooxda seddexaad ee bukaanada qaba neuroblastoma waxay leeyihiin muujinta sare ee MYC oncogene, taas oo ah sababta qeybinta unugyada aan la xakamayn karin iyo sameynta burooyinka.
There was a study on mice with a third type of neural tube cell tumors that showed histone deacetylase inhibitors (HDACIs) and phosphatidylinositol 3-kinase inhibitors (PI3KIs) might stop mice and people from making neurotubular glioblastomas without doing too much damage to normal cells.
We found several histone deacetylase inhibitors that can kill MYC oncogene-activated neural tube cell tumors without harming normal cell agents (HDACIs),” said Pei Yanxin, an assistant professor at the National Children’s Xarunta Caafimaadka ee Washington, DC
The most effective of these compounds is panobinostat, which has entered clinical trials in other noocyada kansarka, but has not yet been tested on neuroblastoma.” Dr. Kun-Wei, a postdoctoral researcher at Stanford University, added: “Several other studies have revealed that the mechanism of action of panobinostat is to promote the activation of the FOXO1 gene that can interfere with the oncogenes of MYC.
Phosphatidylinositol 3-kinase inhibitors (PI3KIs) are also thought to have the effect of activating the FOXO1 gene. We hypothesized that panobinostat and phosphatidylinositol 3-kinase inhibitors (PI3KIs) could work together to block unugga kansarka badbaado.
“It is true that the combined treatment of these two drugs can significantly increase the survival of patients with tumors carrying the MYC gene compared to using a single drug alone.”
